Abstract: A composition comprising a non-covalent immunocomplex of an anthracycline agent and an antibody selected to bind a target antigen and enhance the cytotoxicity of the anthracycline agent is disclosed. In accordance with the invention, the efficacy of an anthracycline as an anti-tumor agent for use in in vivo therapy is enhanced by administering to a patient a non-covalent immunocomplex provided herein.
Type:
Grant
Filed:
September 24, 1986
Date of Patent:
April 2, 1991
Assignee:
Hybritech Incorporated
Inventors:
James M. Frincke, Richard M. Bartholomew, Robert O. Dillman